China's Xuanzhu set for best day in 6 months on drug deal with Boston Oncology

Xuanzhu Biopharmaceutical

10/04/2026 04:06

** Shares of drugmaker Xuanzhu Biopharmaceutical 2575.HK jump 18.1% to HK$37

** Set for the biggest one-day pct rise since Oct 22

** Stock also hit highest level since March 27 in the fifth session of gain

** Cambridge, Massachusetts-based oncology drugmaker Boston Oncology CGT Holding will license Xuanzhu's breast cancer treatment Bireociclib and lung cancer treatment Dirozalkib

** Payments to exceed $100 million if milestones are met

** Under agreement, Sihuan Pharmaceutical 0460.HK unit Xuanzhu is eligible to receive an upfront payment, regulatory and sales-related milestone payments, royalties based on sales

** YTD, Xuanzhu stock down 50.6%, while Sihuan Pharmaceutical shares up 15.5%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))